Not known Facts About Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important demo objectives ended up To guage the safety and tolerabili